Incyte Corp (NAS:INCY)
$ 69.91 0.07 (0.1%) Market Cap: 13.47 Bil Enterprise Value: 11.73 Bil PE Ratio: 499.36 PB Ratio: 4.25 GF Score: 89/100

Incyte Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 16, 2020 / 01:30PM GMT
Release Date Price: $89.94 (-1.63%)
Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Okay. Great. Welcome, everyone. My name is Vikram Purohit. I'm one of the biotech analysts with Morgan Stanley Research, and we are here for a fireside chat with the management team from Incyte. I have on the line with me Hervé Hoppenot and Christiana Stamoulis, CEO and CFO of Incyte. Welcome to both of you.

HervÃ;Hoppenot
Incyte Corporation - Chairman, President & CEO

© -

Thank you. Good morning.

Christiana Stamoulis
Incyte Corporation - Executive VP & CFO

Good morning, Vikram.

Vikram Purohit
Morgan Stanley, Research Division - Equity Analyst

Good morning. Before we go ahead and get started with the discussion, I need to read a brief disclaimer. Please note that this webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. This webcast is not for members of the press. If you are a member of the press, please disconnect and reach out separately. For

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot